Sopharma AD Sopharma AD

Sopharma AD

SPH

Rank in Stocks #6188
Sopharma AD, an international pharmaceutical company founded in Sofia,... Sopharma AD, an international pharmaceutical company founded in Sofia, Bulgaria, in 1933, specializes in the research, development, manufacturing, and commercialization of a wide array of healthcare products. Its offerings span medicinal substances, finished drug formulations, veterinary vaccines, infusion solutions, and disposable plastic medical devices for both human and animal health, in addition to food supplements. The company's diverse product portfolio addresses numerous therapeutic categories, including cardiology, gastroenterology, pain management, cough and cold remedies, immunology and dermatology, respiratory conditions (like asthma), neurology and psychiatry, urology, and gynecology. Key products include Carsil for gastrointestinal issues, the analgesic Tempalgin, Tabex for smoking cessation, Tribestan to support sexual system functions, Broncholytin for coughs, the common pain reliever Analgin, Nivalin for peripheral nervous system disorders, and Methylprednisolon for severe allergies and critical medical situations. Beyond its core pharmaceutical business, Sopharma AD engages in a variety of other ventures. These include providing secondary packaging services for pharmaceuticals, leasing real estate, and operating in the retail sector for medicines and medical equipment. The company also handles the cultivation, collection, and trade of herbs and medicinal plants. Furthermore, it is involved in the trading, transport, and packaging of radioactive materials and nuclear equipment for medical applications, as well as household electronics and electrical equipment. Sopharma AD also offers market and public opinion research, provides franchising and know-how, and participates in various consulting and non-pharmaceutical activities, such as the production of veterinary vaccines and infusion solutions.
Share Price
$3.39
Last synced: 2026-11-13
Market Cap
$1.82B
Change (1 day)
-3.15%
Change (1 year)
-2.45%
Country
BG

Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this

Category

Healthcare
EPS for Sopharma AD (SPH)
EPS as of June 2026 TTM: $0.24
According to Sopharma AD's latest financial reports, its current EPS (TTM) is $0.24. At the end of 2025 the company had an EPS of $0.23, a decrease compared to its 2024 EPS of $0.24.
EPS history for Sopharma AD from 2011 to 2026
EPS at the end of each year
Year EPS Change
2026 (TTM) $0.24 2.96%
2025 $0.23 -4.29%
2024 $0.24 -37.21%
2023 $0.39 18.57%
2022 $0.33 -20.52%
2021 $0.41 175.47%
2020 $0.15 -62.09%
2019 $0.40 193.55%
2018 $0.13 -29.09%
2017 $0.19 -9.56%
2016 $0.21 122.43%
2015 $0.09 -4.83%
2014 $0.10 -38.63%
2013 $0.16 -11.15%
2012 $0.18 -8.08%
2011 $0.20 0.00%
EPS for similar companies or competitors
Company EPS EPS Difference Country
$39.05 16,390.71%
US
$17.99 7,497.13%
US
$7.77 3,181.25%
US
$17.99 7,497.13%
US
$0.04 -82.39%
AU

Questions about Sopharma AD's earnings per share (EPS)

What is Sopharma AD's earnings per share (EPS)?

Sopharma AD's earnings per share (EPS) over the last twelve months is $0.24, as of Jun 2026.

What was Sopharma AD's earnings per share (EPS) in 2025?

In 2025, Sopharma AD's earnings per share (EPS) was $0.23, 4.17% less than in 2024 ($0.24).

How has Sopharma AD's earnings per share (EPS) changed since 2020?

From 2020 to 2025, Sopharma AD's earnings per share (EPS) went from $0.15 to $0.23, an average growth of 8.92% a year.

How does Sopharma AD's earnings per share (EPS) compare with similar companies?

Sopharma AD's earnings per share (EPS) ($0.24) is higher than that of 1 of the 5 similar companies listed above. The highest among them is McKesson Corporation, with $39.05.